Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1

Conditions

Multiple Myeloma 4Lymphoma 2Wilms Tumor 1Plasmacytoma 1Paraproteinemias 1Pancreatic Neoplasms 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Plasma Cell 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Vincristine 10Filgrastim 10Cyclophosphamide 10Doxorubicin 8Etoposide 7Radiotherapy 6Dactinomycin 6Carboplatin 6Granulocyte Colony-Stimulating Factor 5Topotecan 4Polymerase Chain Reaction 4Gene Expression Profiling 4sargramostim 3Temozolomide 3Reverse Transcriptase Polymerase Chain Reaction 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3Itraconazole 3Irinotecan 3Ifosfamide 3DNA Methylation 3Cisplatin 3Busulfan 3liposomal amphotericin B 2ixabepilone 2X-Rays 2Voriconazole 2Therapeutics 2Stem Cell Transplantation 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Wilms Tumor × Proteasome Inhibitors × Clear all
NCT01827137 2024-09-19

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

Sellas Life Sciences Group

Phase 1/2 Completed
20 enrolled 9 charts
GenitourinaryPlasma cell

Multiple Myeloma, Wilms Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡